Advertisement

Pharmacy World and Science

, Volume 27, Issue 3, pp 263–265 | Cite as

Antidiabetic Drug Utilization in Hungary

  • Balázs HankóEmail author
  • Éva Tukarcs
  • Péter Kumli
  • Zoltán Vincze
Article

Abstract

Objective: To evaluate the utilization trends of antidiabetics in Hungary.

Method: The analysis includes the drugs of antidiabetic therapy which were registered between 1998 and 2002 in Hungary. The consumption of antidiabetic drugs was analyzed by the ATC/Defined Daily Dose (DDD) method. The data used in this study were derived from the National Health Insurance and from MIS Consulting Company.

Results: Between 1998 and 2002, the total consumption of antidiabetics increased by 41.8%, and reached 47.59 DDD/1000 inhabitants/day in 2002. The consumption of oral antidiabetics (OAD) increased by 33.41% (33.86 DDD/1000 inhabitants/d ay in 2002), while in the case of insulin the increase was 67.8% (13.74 DDD/1000 inhabitants/day). Sulphonylureas were the most frequently used class (21.11 DDD/1000 inhabitants/day in 2002). Glibenclamide was the most frequently used antidiabetic drug (12.63 DDD/1000 inhabitants/day in 2002).

Conclusion: The insulin class had greater emphasis in therapy. Among OAD, the consumption rate of sulphonylureas decreased and the consumption rate of Biguanides and acarbose increased. By 2002 metformin replaced 90% of the buformin in use. The limited effect of therapeutic recommendations could explain these changes, although the out-of-date buformin and the non-micronized glibenclamide were still in use in 2002.

Keywords

DDD Diabetes mellitus Drug utilization Insulin Oral antidiabetics 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Sarah, W, Gojka, R, Anders, G, Richard, S, Hilary, K. 2004Global prevalence of diabetesDiabet Care27104753Google Scholar
  2. Hilary, K, Ronald, EA, William, HH. 1998Global burden of diabetes, 1995–2025Diabet Care21141431Google Scholar
  3. Alberti, KGMM, Zimmet, PZ. 1998Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: Diagnosis and classification of diabetes mellitus, provisional report of a WHO consultationDiabet Med1553953CrossRefPubMedGoogle Scholar
  4. UK Prospective Diabetes Study Group.1998Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)Lancet35283753Google Scholar
  5. DCCT Research Group.1993The effect of intensive treatment of diabetes ont he developement and progression of long-term complications in insulin-dependent diebetes mellitusN Engl J Med32997786Google Scholar
  6. International Diabetes Federation.1999A desktop guide to type 2 diabetesDiabetic Med1671630Google Scholar
  7. Hungarian Diabetes Association.1999The classification, the treatment and the care of diabetes mellitus national guidelineDiabetol Hungarica74457Google Scholar
  8. Viliam, F, Michaela, P, Tomas, T. 2003Pharmacotherapy of diabetes mellitus and its economic consequences int he Slovak RepublicJ Soc Admin Pharm20779Google Scholar
  9. Stephen, JB, Jenifer, W, James, F, Jennifer, CYS, Amishi, BS, Jennifer, K. 2001Utilization of oral hypoglycemic agents in a drug-insured U.S. populationDiabet Care24141115Google Scholar
  10. Per, EW, Catharina, G. 2002Drug prescription in men and women with type-2 diabetes in Stockholm in 1995 and 2001: change over timeEur J Clin Pharmacol5854753CrossRefPubMedGoogle Scholar

Copyright information

© Springer 2005

Authors and Affiliations

  • Balázs Hankó
    • 1
    Email author
  • Éva Tukarcs
    • 1
  • Péter Kumli
    • 1
  • Zoltán Vincze
    • 1
  1. 1.Institute of Pharmacy AdministrationSemmelweis UniversityBudapestHungary

Personalised recommendations